OVCA1 and OVCA2 Tumor Suppressor Genes

Topics in This Section

Introduction:

In the 1990s, Dr. Andrew Godwin and colleagues at Fox Chase Cancer Center identified two novel genes, designated OVCA1 and OVCA2, which are closely related to breast and ovarian cancer. Recent research in mutant mice has demonstrated that OVCA1 is a tumor suppressor gene and potential cell cycle regulator. Coordinated loss of OVCA1 and p53 genes appears to lead to ovarian, breast and other potentially other cancers. Polyclonal antibodies to OVCA1 and OVCA2 have been developed. The genes and related antibodies are protected by US patents issued to Fox Chase Cancer Center.

Background:

Chromosome 17 is a hotspot for chromosomal aberrations in breast and ovarian cancer. Candidate oncogenes and tumor suppressors located on this chromosome include OVCA1 and OVCA2, p53, BRCA1, HER2/neu and others. OVCA1 and 2 map to a highly conserved region on human chromosome 17p13.3 that is deleted in 80% of ovarian cancers and shows frequent loss of heterozygosity in breast cancers . OVCA1 is induced by BRCA1 and is closely linked to p53, a well-known tumor suppressor gene. The close linkage of OVCA1 and p53 suggests that coordinated loss of the two genes may lead to ovarian, breast and other tumor types.

Applications:

  • Cancer Research: OVCA1 and OVCA-2 genes and polyclonal antibodies are useful in studies on tumorigenesis, cell cycle regulation, and cancer diagnosis and prognosis.
  • Cancer Drug Discovery: OVCA1 and OVCA2 genes and proteins are markers and targets for drug discovery.

Opportunity:

Research and commercial licenses are available for both the patents and polyclonal antibodies. We are seeking a partner for further clinical development of OVCA 1 & 2.

Publications:

Patent Status:

OVCA1 and OVCA2 genes and antibodies are covered by US Patents 5,801,041 and 5,821,338.